Intraocular Lens Opacification following Intracameral Injection of Recombinant Tissue Plasminogen Activator to Treat Inflammatory Membranes after Cataract Surgery

Table 1

Characteristics of patients with IOL opacification following intracameral rtPA treatment after uncomplicated cataract surgery.

Case	Eye	Ocular comorbidity	Additional procedures	IOL type	Presenting; BCVA	Time from; surgery to rtPA	rtPA dose (μg)	Time of IOL; opacification; after rtPA	After rtPA BCVA	IOL; exchange	Final BCVA
1	OS	—	—	C-flex 570C	0.00	1 week	25	3 months	0.00	Yes	0.00
2	OD	—	—	C-flex 570C	0.40	4 weeks	25	4 months	0.00	Yes	0.30
3	OD	—	—	Superflex 620H	0.10	2 weeks	25	8 months	0.30	Yes	0.10
4	OS	Phacomorphic glaucoma	—	C-flex 570C	0.80	2 weeks	10	6 weeks	0.90	Declined	0.60
5	OD	Treated PDR, previous; vitrectomy and delamination	—	Superflex 620H	0.48	1 week	20	17 months	0.30	Declined	0.60
6	OD	Treated PDR, persistent DMO	Combined with IVTA	C-flex 570C	1.00	2 weeks	50	4 weeks	0.78	Unsuitable	2.00
7	OS	PDR, vitreous haemorrhage	Combined with PPV,; delamination and laser	Superflex 620H	1.00	1 week	40	12 months	0.40	Declined	0.50

PDR: proliferative diabetic retinopathy, DMO: diabetic macular oedema, IOL: intraocular lens, BCVA: best corrected visual acuity (measured in logMAR), and μg: microgram.